Combination of omeprazole with GLP-1 agonist Therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice

Pharmacological Reports

Volumn 65, Issue 4, 2013, Pages 927-936

  Patel, Vishal ^a   Joharapurkar, Amit ^a   Dhanesha, Nirav ^a   Kshirsagar, Samadhan ^a   Detroja, Jaysukh ^a   Patel, Kartikkumar ^a   Gandhi, Tejal ^b   Patel, Kirti ^b   Bahekar, Rajesh ^a   Jain, Mukul ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b ANAND PHARMACY COLLEGE   (India)

Author keywords

Exendin 4; Glp 1; Insulin sensitivity; Irs 1; Nrf 2; Omeprazole; Type 1 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN RECEPTOR; LIPID; OMEPRAZOLE; PROTON PUMP INHIBITOR; STREPTOZOCIN; TRANSCRIPTION FACTOR NRF2; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GLUCOSE BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID PEROXIDATION; LIVER; MALE; MOUSE; NONHUMAN; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIVER; MALE; MICE; NF-E2-RELATED FACTOR 2; OMEPRAZOLE; PEPTIDES; PROTON PUMP INHIBITORS; VENOMS;

EID: 84886538192     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71074-0     Document Type: Article

References (34)

1. Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, Watada H: Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. Biochem Biophys Res Commun, 2009, 390, 809-814.
2. Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK: A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem, 2003, 278, 10993-11001.
3. Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol, 1978, 52, 302-310.
4. Dhanesha N, Joharapurkar A, Shah G, Dhote V, Kshirsagar S, Bahekar R, Jain M: Exendin-4 ameliorates diabetic symptoms through activation of glucokinase. J Diabetes, 2012, 4, 369-377.
5. Dhanesha N, Joharapurkar A, Shah G, Dhote V, Kshirsagar S, Bahekar R, Jain M: Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect. Pharmacol Rep, 2012, 64, 140-149.
6. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 2006, 43, 173-181.
7. Drucker DJ: The biology of incretin hormones. Cell Metab, 2006, 3, 153-165.
8. Folli F, Guardado Mendoza R: Potential use of exenatide for The treatment of obesity. Expert Opin Investig Drugs, 2011, 20, 1717-1722.
9. Gentilella R, Bianchi C, Rossi A, Rotella CM: Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab, 2009, 11, 544-556.
10. Gezginci-Oktayoglu S, Sacan O, Yanardag R, Karatug A, Bolkent S: Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice. Peptides, 2011, 32, 223-231.
11. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-Amide an antagonist at The glucagon-like peptide 1-(7-36)-Amide receptor of insulin-secreting b-cells. J Biol Chem, 1993, 268, 19650-19655.
12. Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K: The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synThesis and secretion in hamsters and mice. Diabetologia, 2010, 53, 552-561.
13. Hu X, Feng Y, Shen Y, Zhao XF, Yu JH, Yang YS, Leng Y: Antidiabetic effect of a novel nonthiazolidinedione PPAR gamma/alpha agonist on ob/ob mice. Acta Pharmacol Sin, 2006, 27, 1346-1352.
14. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, Yamamoto M: Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol, 2006, 26, 221-229.
15. Leckstrom A, Lew PS, Poritsanos NJ, Mizuno TM: Central melanocortin receptor agonist reduces hepatic lipogenic gene expression in streptozotocin-induced diabetic mice. Life Sci, 2011, 88, 664-669.
16. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, Yoon JW, Jun HS: Glucagon-like peptide-1 gene Therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes, 2007, 56, 1671-1679.
17. Ligumsky M, Lysy J, Siguencia G, Friedlander Y: Effect of long-term, continuous versus alternate-day omeprazole Therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol, 2001, 33, 32-35.
18. Mefford IN, Wade EU: Proton pump inhibitors as a treatment method for type II diabetes. Med HypoTheses, 2009, 73, 29-32.
19. Nielsen LL, Young AA, Parkes DG: Pharmacology of exenatide (synThetic exendin-4): a potential Therapeutic for improved glycemic control of type 2 diabetes. Regul Pept, 2004, 117, 77-88.
20. Ogawa N, List JF, Habener JF, Maki T: Cure of overt diabetes in NOD mice by transient treatment with antilymphocyte serum and exendin-4. Diabetes, 2004, 53, 1700-1705.
21. Patel V, Joharapurkar A, Gandhi T, Patel K, Dhanesha N, Kshirsagar S, Dhote V et al.: Omeprazole improves The antiobesity and antidiabetic activity of exendin-4 in db/db mice. J Diabetes, 2013, 5, 163-171.
22. Perry T, Greig N: The glucagon-like peptides: a doubleedged Therapeutic sword? Trends Pharmacol Sci, 2003, 24, 377-383.
23. Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu X, Bomgaars L, Heptulla RA: The role of adjunctive exenatide Therapy in pediatric type 1 diabetes. Diabetes Care, 2010, 33, 1294-1396.
24. Rooman I, Lardon J, Bouwens L: Gastrin stimulates b-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes, 2002, 51, 686-690.
25. Rydgren T, Vaarala O, Sandler S: Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. J Pharmacol Exp Ther, 2007, 323, 180-185.
26. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M et al.: Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes, 1999, 48, 1045-1053.
27. Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A: Combination Therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia, 2009, 52, 1680-1682.
28. Suarez-PinzonWL, Power RF, Yan Y,Wasserfall C, AtkinsonM, Rabinovitch A: Combination Therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes, 2008, 57, 3281-3218.
29. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulate b-cell neogenesis in streptozotocin treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes, 2001, 50, 1562-1570.
30. Tuzcu M, Sahin N, Orhan C, Agca CA, Akdemir F, Tuzcu Z, Komorowski J, Sahin K: Impact of chromium histidinate on high fat diet induced obesity in rats. Nutr Metab, 2011, 8, 28-35.
31. Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, Koya D et al.: Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology, 2010, 151, 2040-2049.
32. Wang TC, Bonner-Weir S, Oates PS, Chulak M, Simon B, Merlino GT, Schmidt EV, Brand SJ: Pancreatic gastrin stimulates islet differentiation of transforming growth factor a-induced ductular precursor cells. J Clin Invest, 1993, 92, 1349-1356.
33. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both b-cell replication and neogenesis, resulting in increased b-cell mass and improved glucose tolerance in diabetic rats. Diabetes, 1999, 48, 2270-2276.
34. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulinsensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes, 1999, 48, 1026-1034